Sintx Technologies (SINT) FDA Approvals $1.22 -0.12 (-8.96%) Closing price 11/17/2026 03:55 PM EasternExtended Trading$1.34 +0.12 (+9.75%) As of 09:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings Sintx Technologies' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Sintx Technologies (SINT). Over the past two years, Sintx Technologies has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as SINAPTIC. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. SINAPTIC FDA Regulatory Events SINAPTIC is a drug developed by Sintx Technologies for the following indication: Foot & Ankle Osteotomy Wedge System. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - March 19,2026Provided Update Drug: SINAPTICAnnounced Date: March 19, 2026Indication: Foot & Ankle Osteotomy Wedge SystemAnnouncementSINTX Technologies, Inc. announced the successful completion of the first-in-human surgical procedure utilizing its FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, marking a major clinical and commercial milestone in the Company's expansion into the global orthopedic device market.AI SummarySINTX Technologies announced the successful completion of the first-in-human surgical use of its FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, marking a major clinical and commercial milestone as the company expands into the global foot and ankle reconstruction market. The procedure was performed March 13, 2026 by Dr. Scott Carrington, DPM, FACFAS, at Emplify Health in La Crosse, Wisconsin. Surgeons reported the implant provided the needed structural integrity and clear imaging crucial for reconstructive cases. The SINAPTIC wedge uses SINTX’s silicon nitride biomaterial, noted for osteoconductive and pro-osteogenic properties, a bacteriostatic surface, hydrophilicity, and compatibility with X-ray, CT, and MRI. These features may help bone integration, reduce bacterial adhesion, and improve post-operative imaging, potentially aiding clinical decision-making and patient recovery. SINTX views this case as an important step toward commercial adoption of the SINAPTIC platform, broader orthopedic applications beyond spine, and a planned U.S. commercial launch to support long-term growth. Read AnnouncementProvided Update - October 20,2025Provided Update Drug: SINAPTICAnnounced Date: October 20, 2025Indication: Foot & Ankle Osteotomy Wedge SystemAnnouncementSINTX Technologies, Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the SINAPTIC® Foot & Ankle Osteotomy Wedge System, enabling SINTX's commercial entry into reconstructive foot and ankle surgery in the United States. SINTX plans a U.S. commercial launch in Q1 2026, leveraging its U.S.-based manufacturing to drive revenue acceleration and operating efficiency.AI SummarySINTX Technologies announced U.S. Food and Drug Administration 510(k) clearance for its SINAPTIC® Foot & Ankle Osteotomy Wedge System, marking the company’s entry into reconstructive foot and ankle surgery in the United States. The implant combines SINTX’s proprietary silicon nitride biomaterial with surgeon-informed designs and a sterile, single-use instrument kit engineered to enhance surgical efficiency, precision and reproducibility. By blending advanced material science with practical innovation, SINAPTIC aims to address unmet clinical needs in foot and ankle procedures and support long-term company growth. SINTX plans a U.S. commercial launch in Q1 2026, leveraging its U.S.-based manufacturing to accelerate revenue and improve operating efficiency. The non-metal, pro-osteogenic and bacteriostatic properties of silicon nitride also offer better bone integration and clear imaging on X-rays and CT scans. Targeting a multibillion-dollar market, SINTX expects the new system to drive meaningful clinical impact and create shareholder value as part of its broader biomaterials platform strategy.Read Announcement Sintx Technologies FDA Events - Frequently Asked Questions Has Sintx Technologies received FDA approval? As of now, Sintx Technologies (SINT) has not received any FDA approvals for its therapy in the last two years. What drugs has Sintx Technologies submitted to the FDA? In the past two years, Sintx Technologies (SINT) has reported FDA regulatory activity for SINAPTIC. What is the most recent FDA event for Sintx Technologies? The most recent FDA-related event for Sintx Technologies occurred on March 19, 2026, involving SINAPTIC. The update was categorized as "Provided Update," with the company reporting: "SINTX Technologies, Inc. announced the successful completion of the first-in-human surgical procedure utilizing its FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, marking a major clinical and commercial milestone in the Company's expansion into the global orthopedic device market." What conditions do Sintx Technologies' current drugs treat? Currently, Sintx Technologies has one therapy (SINAPTIC) targeting the following condition: Foot & Ankle Osteotomy Wedge System. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Innate Pharma FDA EventsRecursion Pharmaceuticals FDA EventsSummit Therapeutics FDA EventsACADIA Pharmaceuticals FDA EventsBiogen FDA EventsEikon Therapeutics FDA EventsGain Therapeutics FDA EventsIonis Pharmaceuticals FDA EventsKaryopharm Therapeutics FDA EventsPulmonx FDA EventsMetaVia FDA EventsNeonc Technologies FDA EventsRegeneron Pharmaceuticals FDA EventsSELLAS Life Sciences Group FDA EventsSanofi FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Inspira Technologies OXY B.H.N. FDA Events Nyxoah FDA Events HeartBeam FDA Events Nano-X Imaging FDA Events Cytosorbents FDA Events PAVmed FDA Events SeaStar Medical FDA Events NeuroOne Medical Technologies FDA Events ENDRA Life Sciences FDA Events Aethlon Medical FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:SINT last updated on 3/19/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThis Could Be the Biggest Monetary Shift in 50 YearsThe U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trad...Patriot Gold Group | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sintx Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sintx Technologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - March 19,2026Provided Update Drug: SINAPTICAnnounced Date: March 19, 2026Indication: Foot & Ankle Osteotomy Wedge SystemAnnouncementSINTX Technologies, Inc. announced the successful completion of the first-in-human surgical procedure utilizing its FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, marking a major clinical and commercial milestone in the Company's expansion into the global orthopedic device market.AI SummarySINTX Technologies announced the successful completion of the first-in-human surgical use of its FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, marking a major clinical and commercial milestone as the company expands into the global foot and ankle reconstruction market. The procedure was performed March 13, 2026 by Dr. Scott Carrington, DPM, FACFAS, at Emplify Health in La Crosse, Wisconsin. Surgeons reported the implant provided the needed structural integrity and clear imaging crucial for reconstructive cases. The SINAPTIC wedge uses SINTX’s silicon nitride biomaterial, noted for osteoconductive and pro-osteogenic properties, a bacteriostatic surface, hydrophilicity, and compatibility with X-ray, CT, and MRI. These features may help bone integration, reduce bacterial adhesion, and improve post-operative imaging, potentially aiding clinical decision-making and patient recovery. SINTX views this case as an important step toward commercial adoption of the SINAPTIC platform, broader orthopedic applications beyond spine, and a planned U.S. commercial launch to support long-term growth. Read Announcement
Provided Update - October 20,2025Provided Update Drug: SINAPTICAnnounced Date: October 20, 2025Indication: Foot & Ankle Osteotomy Wedge SystemAnnouncementSINTX Technologies, Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the SINAPTIC® Foot & Ankle Osteotomy Wedge System, enabling SINTX's commercial entry into reconstructive foot and ankle surgery in the United States. SINTX plans a U.S. commercial launch in Q1 2026, leveraging its U.S.-based manufacturing to drive revenue acceleration and operating efficiency.AI SummarySINTX Technologies announced U.S. Food and Drug Administration 510(k) clearance for its SINAPTIC® Foot & Ankle Osteotomy Wedge System, marking the company’s entry into reconstructive foot and ankle surgery in the United States. The implant combines SINTX’s proprietary silicon nitride biomaterial with surgeon-informed designs and a sterile, single-use instrument kit engineered to enhance surgical efficiency, precision and reproducibility. By blending advanced material science with practical innovation, SINAPTIC aims to address unmet clinical needs in foot and ankle procedures and support long-term company growth. SINTX plans a U.S. commercial launch in Q1 2026, leveraging its U.S.-based manufacturing to accelerate revenue and improve operating efficiency. The non-metal, pro-osteogenic and bacteriostatic properties of silicon nitride also offer better bone integration and clear imaging on X-rays and CT scans. Targeting a multibillion-dollar market, SINTX expects the new system to drive meaningful clinical impact and create shareholder value as part of its broader biomaterials platform strategy.Read Announcement